Regulatory Post-Marketing Surveillance Study for Brolucizumab

Who May Qualify: 1. Patients aged ≥18 years with nAMD that are prescribed with Brolucizumab as per approved local product information 2. Patients who consent to participate in the study after the purpose and nature of the study have clearly explained to them (written willing to sign a consent form) Who Should NOT Join This Trial: 1. Contraindications as per local prescribing information 1) Hypersensitivity to the active substance or to any of the excipients. 2) Active or suspected ocular or periocular infection. 3) Active intraocular inflammation. 2. Patients participating in other investigational drug trial Always talk to your doctor about whether this trial is right for you.